PharmaShots Weekly Snapshot ( February 11-15, 2019)


1. Arvelle Therapeutics Licenses Exclusive Development & Commercialization Rights for Cenobamate from SK Biopharmaceuticals in EU

Published: 14 Feb,2019 | Tags: Arvelle Therapeutics, Licenses, Exclusive, Development, Commercialization, Rights, Cenobamate, SK Biopharmaceuticals, EU

2. Novartis Signs a Multi-Target Agreement with AbCellera for its Ab-Based Technology

Published: 14 Feb,2019 | Tags: Novartis, Signs, Multi-Target, Agreement, AbCellera, Ab-Based, Technology

3. Bristol-Myers (BMS) Reports Results of Opdivo (nivolumab) + Yervoy (ipilimumab) in P-II CheckMate -650 trial for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Published: 14 Feb,2019 | Tags: Bristol-Myers, BMS, Reports, Results, Opdivo, nivolumab, Yervoy, ipilimumab, P-II, CheckMate -650 trial, Metastatic Castration-Resistant Prostate Cancer, mCRPC

4. Nestle Health Science (NHSc) Exercises its Exclusive WorldWide Option to License CDX-6114 from Codexis

Published: 14 Feb,2019 | Tags: Nestle Health Science,NHSc, Exercises, Exclusive, WorldWide, Option, License, CDX-6114, Codexis

5. Bayer Reports Results of Darolutamide in P-III ARAMIS trial for Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)

Published: 15 Feb,2019 | Tags: Bayer, Reports, Results, Darolutamide, P-III, ARAMIS trial, Non-Metastatic Castration-Resistant Prostate Cancer, nmCRPC, ADT, Androgen Deprivation Therapy

6. Roche Signs a Clinical Program Agreement with Vaccibody to Evaluate VB10.16 + Tecentriq (atezolizumab) for Advanced Cervical Cancer

Published: 13 Feb,2019 | Tags: Roche, Signs, Clinical Program, Agreement, Vaccibody,Evaluate, VB10.16 + Tecentriq, atezolizumab, Advanced Cervical Cancer, ACC

7. Amgen Signs a Multi-Target Collaboration with Abilita Bio for Enabled Membrane Proteins (EMPs)

Published: 14 Feb,2019 | Tags: Amgen, Signs, Multi-Target, Collaboration, Abilita Bio, Enabled Membrane Proteins, EMPs

8. Clinigen Licenses Commercialization Rights for Proleukin from Novartis in the US  

Published: 14 Feb,2019 | Tags: Clinigen, Licenses, Commercialization, Rights, Proleukin, Novartis, the US

9. Johnson & Johnson to Acquire Auris Health for its Monarch Technology for $5.7B

Published: 14 Feb,2019 | Tags: Johnson&Johnson, Acquire, Auris Health, Monarch Technology, $5.7B, Lung Cancer

10. Novartis’ Egaten (triclabendazole) Receives FDA’s Approval for Fascioliasis in the US

Published: 14 Feb,2019 | Tags: Novartis, Egaten, triclabendazole, Receives, FDA, Approval, Fascioliasis, the US

11. ITROM Pharmaceutical Signs an Exclusive License & Commercialization Agreement with Mithra for 20 years

Published: 13 Feb,2019 | Tags: ITROM Pharmaceutical, Signs, Exclusive, License, Commercialization, Agreement, Mithra, 20 years

12. Almirall Signs an Option to License Agreement with Dermira to Develop and Commercialize Lebrikizumab in EU for Atopic Dermatitis

Published: 13 Feb,2019 | Tags: Almirall, Signs, Option, License, Agreement, Dermira, Develop, Commercialize, Lebrikizumab, EU, Atopic Dermatitis

13. Bayer Signs an Exclusive License Agreement with Moberg Pharma for MOB-015 in EU

Published: 13 Feb,2019 | Tags: Bayer, Signs, Exclusive, License, Agreement, Moberg Pharma, MOB-015, EU

14. Janssen (J&J) Reports Voting Results from FDA Advisory Committees for Spravato (esketamine) in Adults with Resistant Depression

Published: 13 Feb,2019 | Tags: Janssen, J&J, Reports, Voting, Results, FDA, Advisory Committees, Spravato, esketamine,Adults, Resistant Depression

15. AbbVie Signs a Partner and Option to Acquire Agreement with TeneoOne for its TNB-383B

Published: 13 Feb,2019 | Tags: AbbVie, Signs, Partner, Option, Acquire, Agreement, Teneobio, TNB-383B

16. Gilead Reports Results of Selonsertib in P-III STELLAR-4 study for Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis (NASH)

Published: 13 Feb,2019 | Tags: Gilead, Reports, Results, Selonsertib, P-III, STELLAR-4 study, Compensated Cirrhosis, F4, Nonalcoholic Steatohepatitis, NASH

18. Genmab’s Darzalex (daratumumab) Split Dosing Regimen Receives the US FDA Approval for Multiple Myeloma

Published: 13 Feb,2019 | Tags: Genmab, Darzalex, daratumumab, Split Dosing, Regimen, Receives, the US FDA, Approval, Multiple Myeloma

19. Takeda’s Adcetris (brentuximab vedotin) + AVD Receives EU Approval for CD30+ Stage IV Hodgkin Lymphoma (HL) in Adults

Published: 13 Feb,2019 | Tags: Takeda, Adcetris, brentuximab vedotin,  AVD, Receives, EU Approval, CD30+, Stage, IV, Hodgkin Lymphoma, HL, Adults  

20.Astellas Reports Results of Xtandi (enzalutamide) in P-III ARCHES Trial for Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) in Men

Published: 13 Feb,2019 | Tags: Astellas, Reports, Results, Xtandi, enzalutamide, P-III, ARCHES Trial, Metastatic Hormone-Sensitive Prostate Cancer, mHSPC, Men

21. Bristol-Myers Reports Results of Opdivo (nivolumab) + Yervoy (ipilimumab) in P-III CheckMate-214 study in Patients with Advanced or Metastatic RCC

Published: 12 Feb,2019 | Tags: Bristol-Myers, Reports, Results, Opdivo, nivolumab, Yervoy, ipilimumab, P-III, CheckMate-214 study, Patients, Advanced, Metastatic, RCC

22. Finch Therapeutics’ CP101 Receives FDA’s Breakthrough Therapy Designation (BT) for Recurrent Clostridium Difficile (C. difficile) Infection

Published: 12 Feb,2019 | Tags: Finch Therapeutics, CP101, Receives, FDA, Breakthrough Therapy Designation, BT, Recurrent Clostridium difficile, C. difficile, Infection

23. Pfizer Recalls Lots of Ambaro (valsartan and amlodipine besylate salt) for its Carcinogenic Effects in Japan

Published: 12 Feb,2019 | Tags: Pfizer, Recalls, Lots, Ambaro, valsartan and amlodipine besylate salt, Carcinogenic, Effects, Japan  

24. Regeneron Reports Results of Eylea (aflibercept) in P-III PANORAMA Trial for Diabetic Retinopathy (DR)

Published: 11 Feb,2019 | Tags: Regeneron, Reports, Results, Eylea, aflibercept, P-III, PANORAMA Trial, Diabetic Retinopathy, DR

25. C-Bridge Capital Signs a Development & Commercialization Agreement with Samsung Bioepis for Biosimilars in China

Published: 11 Feb,2019 | Tags: C-Bridge, Capital, Signs, Development, Commercialization, Agreement, Samsung Bioepis, Biosimilars, China

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post